Fig. 5From: Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectivesSchema for Biomarker-Driven Neoadjuvant Treatment for Early-Stage NSCLC. A multidisciplinary infrastructure is essential to implement biomarker-driven neoadjuvant treatment based on the histopathological and immunological evaluation and NGS-based molecular screening at the diagnosis of resectable NSCLCBack to article page